Dostarlimab-gxly bulk supplier for pharma manufacturers

Dostarlimab-Gxly 500 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 500 mg

Reference Brands: Jemperli(USA/EU)

Dostarlimab is a humanized monoclonal antibody that targets PD‑1 on T cells, blocking its interaction with PD‑L1/PD-L2. This releases the “brake” on the immune system, allowing T cells to attack cancer cells. It is used mainly for mismatch repair–deficient (dMMR) endometrial cancer and certain other solid tumors with dMMR.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Dostarlimab-Gxly? List it or send an offer →

Product Description:

Dostarlimab is a humanised antibody against PD-1. Tumours exploit this receptor to switch off the T cells that would otherwise destroy them; blocking it removes the restraint. Which tumours respond is largely predictable: cancers with defective mismatch repair accumulate enormous numbers of mutations, present far more abnormal peptides on their surface, and are therefore visible to a reawakened immune system. Mismatch repair status, not tumour site, selects the patient.

It is used for mismatch repair-deficient recurrent or advanced endometrial cancer, in combination with chemotherapy or alone, and for dMMR solid tumours that have progressed after prior treatment. It drew wide attention from a small study in locally advanced dMMR rectal cancer in which every patient achieved clinical complete response. The toxicities are immune-mediated rather than cytotoxic: colitis, hepatitis, pneumonitis, nephritis and endocrinopathies including hypothyroidism and adrenal insufficiency, which may be permanent and require prompt corticosteroid treatment.

Sourcing notes. Originator biologic under patent, supplied as a 500 mg single-dose vial for intravenous infusion. Cold chain at 2–8 degrees, protect from light, do not freeze or shake. Requires mismatch repair or microsatellite instability testing at the destination — without it the product cannot be prescribed on label.

How Dostarlimab-Gxly is supplied today, and licensing ahead of patent expiry

Dostarlimab-Gxly is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Dostarlimab-Gxly, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Dostarlimab-Gxly supply →

Back to Listing

Frequently Asked Questions

Dostarlimab-gxly is used for the treatment of certain advanced or recurrent endometrial cancers that are mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H). It helps the immune system recognize and attack cancer cells by blocking the PD-1 receptor.

It is made from a monoclonal antibody that selectively binds to the programmed death-1 (PD-1) receptor on T-cells, preventing tumor cells from evading immune detection.

The trade name is Jemperli.

Jemperli is manufactured by GlaxoSmithKline (GSK).

The generic name is Dostarlimab-gxly.

The brand name is Jemperli.

It is manufactured by GlaxoSmithKline in its approved biologics production facilities for global distribution.

Jemperli (Dostarlimab) is developed and sold by GSK. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.